C. François

发表

A systematic literature review of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment

M. Toumi, Yitong Wang, T. Qiu, 2022, International Journal of Technology Assessment in Health Care.

Can discrete event simulation be of use in modelling major depression?

C. François, G. Duru, N. Despiégel, 2006, Cost effectiveness and resource allocation : C/E.

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease

S. Gauthier, B. Rive, C. François, 2013, CNS Drugs.

Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results

M. Toumi, C. François, R. Han, 2020, Applied Health Economics and Health Policy.

Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results

M. Toumi, C. François, R. Han, 2020, Applied Health Economics and Health Policy.

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

C. Lançon, P. Llorca, D. Zighed, 2017, Journal of market access & health policy.

Health economic evaluation of gene replacement therapies: methodological issues and recommendations

S. Simoens, F. Antoñanzas, M. Postma, 2020, Journal of market access & health policy.

Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries

M. Toumi, Yitong Wang, T. Qiu, 2021, Applied Health Economics and Health Policy.

Relapse in schizophrenia: costs, clinical outcomes and quality of life

M. Knapp, M. Toumi, C. François, 2004, British Journal of Psychiatry.

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

A. Millier, M. Toumi, S. Aballéa, 2019, Journal of market access & health policy.

Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies

C. Lançon, P. Llorca, B. Rive, 2014, Current medical research and opinion.

The 6-month persistence on SSRIs and associated economic burden

L. Ereshefsky, D. Saragoussi, C. François, 2010, Journal of medical economics.

Cost Of Managing Parkinson’s Disease In China

C. François, D. Milea, K. Hansen, 2014 .

A review of accessibility of administrative healthcare databases in the Asia-Pacific region

P. Verpillat, C. François, D. Milea, 2015, Journal of market access & health policy.

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses

M. Toumi, C. François, K. Thokagevistk, 2018, Journal of market access & health policy.

Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

S. Parikh, C. François, A. Eramo, 2021, BMC Psychiatry.

Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.

S. Seabury, L. Citrome, C. François, 2016, Innovations in clinical neuroscience.

PNL1 EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE

G. Livingston, C. Katona, B. Rive, 2005 .

The Economic Burden of Schizophrenia in the United States in 2013.

C. François, E. Wu, A. Ramanakumar, 2016, The Journal of clinical psychiatry.

Relationship between FEV1 decline and mortality in patients with bronchiolitis obliterans syndrome-a systematic literature review.

C. François, R. Kemp, G. Boerner, 2021, Respiratory medicine.

Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data

A. Ducros, M. Nikodem, C. François, 2022, Cephalalgia : an international journal of headache.

Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments.

S. Simoens, O. Solà-Morales, L. Garrison, 2021, Health policy.

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension

R. Hauser, L. Hewitt, C. François, 2016, BMC Neurology.

Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram

C. Lançon, P. Verpillat, L. Annemans, 2007, International journal of psychiatry in clinical practice.

Results and validation of an index to measure health state of patients with depression in automated healthcare databases

C. Lançon, P. Llorca, P. Verpillat, 2019, Journal of market access & health policy.

Challenges in measuring and valuing productivity costs, and their relevance in mood disorders

C. François, N. Danchenko, M. Drummond, 2013, ClinicoEconomics and outcomes research : CEOR.

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

S. Montgomery, C. François, Jose-Luis Fernandez, 2012, PharmacoEconomics.

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.

C. François, N. Danchenko, Jose-Luis Fernandez, 2008, PharmacoEconomics (Auckland).

Patient-centered assessment of cognitive symptoms of depression

B. Forsyth, S. Fehnel, C. François, 2013, CNS Spectrums.

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

M. Toumi, C. François, Junwen Zhou, 2019, BMC Infectious Diseases.

Indirect comparison of clobazam and other therapies for Lennox–Gastaut syndrome

J. Cramer, C. François, C. Sapin, 2013, Acta neurologica Scandinavica.

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension

A. Duhig, B. Yue, I. Biaggioni, 2019, Movement disorders clinical practice.

Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K.

G. Livingston, C. Katona, C. François, 2006, International Psychogeriatrics.

Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study

Steve S. Chung, M. Brodie, P. Verpillat, 2016, Epilepsy Research.

Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome

J. Stern, A. Duhig, C. François, 2017, Journal of market access & health policy.

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis

C. François, A. Guérin, M. Zhdanava, 2017, BMC Psychiatry.

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach

E. Clay, M. Toumi, S. Aballéa, 2021, Journal of market access & health policy.

Adapting the Goal Attainment Approach for Major Depressive Disorder

S. Parikh, M. Opler, C. François, 2019, Neurology and Therapy.

Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea

H. Jeon, Seong-Jin Cho, C. François, 2016, Expert review of pharmacoeconomics & outcomes research.

Cost effectiveness of memantine in Alzheimer's disease in the UK

G. Livingston, C. Katona, B. Rive, 2010, Journal of medical economics.

The use and performance of productivity scales to evaluate presenteeism in mood disorders.

M. Drummond, C. François, N. Danchenko, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The economic burden of alcohol dependence in Europe.

J. Daeppen, C. François, J. Kusel, 2013, Alcohol and alcoholism.

A Predictive Microsimulation Model to Estimate the Clinical Relevance of Reducing Alcohol Consumption in Alcohol Dependence

J. Rehm, A. Millier, M. Toumi, 2014, European Addiction Research.

Predicting time to full-time care in AD: a new model

G. Livingston, C. Katona, B. Rive, 2010, Journal of medical economics.

Lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015, Neuropsychiatric disease and treatment.

The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model

J. Rehm, C. Barbosa, M. Toumi, 2014, BMJ Open.

The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients

C. François, H. Aubin, A. Luquiens, 2015, PloS one.

Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data

J. Rehm, A. Millier, M. Toumi, 2015, BMC Public Health.

A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence

J. Rehm, A. Millier, M. Toumi, 2016, Applied Health Economics and Health Policy.

Impact of cardiac surgical timing on the neurodevelopmental outcomes of newborns with Complex congenital heart disease (CHD)

N. Resseguier, B. Desnous, M. Lenoir, 2023, Frontiers in Pediatrics.

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives

M. Toumi, S. Aballéa, C. François, 2020, Frontiers in Medicine.

Stigma in visible skin diseases – a literature review and development of a conceptual model

M. Augustin, M. Toumi, C. François, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Clinical Relevance of As-Needed Treatment with Nalmefene in Alcohol-Dependent Patients

D. Nutt, C. François, A. Bladström, 2015, European Addiction Research.

Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

P. Auquier, S. Montgomery, S. Aballéa, 2008, International journal of clinical practice.

Modeling stroke management: a qualitative review of cost-effectiveness analyses

M. Toumi, D. Saragoussi, C. François, 2010, The European Journal of Health Economics.

A clinical research practice datalink analysis of antidepressant treatment patterns and health care costs in generalized anxiety disorder.

E. Clay, D. Saragoussi, C. François, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

C. Lançon, M. Toumi, C. François, 2002, The European Journal of Health Economics.

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram

C. Lançon, P. Llorca, B. Rive, 2015, Journal of market access & health policy.

Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant

L. Ereshefsky, C. François, N. Danchenko, 2020, Expert review of pharmacoeconomics & outcomes research.

A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilization (HCRU) in schizophrenia

A. Jakubowska, S. Kymes, J. Weatherall, 2019, Journal of medical economics.

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor

M. Toumi, C. François, K. Hansen, 2003, The European Journal of Health Economics.

Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

C. Lançon, P. Llorca, T. Brown, 2017, BMC Psychiatry.

A. Duhig, I. Biaggioni, C. François, 2017, Journal of medical economics.

Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis

P. Auquier, D. Saragoussi, C. François, 2010, Journal of medical economics.

Practice Datalink Analysis of Antidepressant Treatment Patterns and Health Care Costs in Generalized Anxiety Disorder

E. Clay, D. Saragoussi, C. François, 2013 .

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease

H. Sintonen, R. Sulkava, B. Rive, 2004, Clinical drug investigation.

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson’s Disease in the UK Setting

A. Haycox, C. François, C. Armand, 2009, Drugs & Aging.

Development of a family functioning scale for major depressive disorder

S. Fehnel, C. François, N. Danchenko, 2012, Current medical research and opinion.

Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact

H. Sintonen, M. Toumi, C. François, 2002 .

Escitalopram and Duloxetine in Major Depressive Disorder

C. François, N. Danchenko, K. Hansen, 2012, PharmacoEconomics.

P. Auquier, C. Allgulander, M. Toumi, 2007, Current medical research and opinion.

Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK

M. Toumi, D. Saragoussi, C. François, 2010, Current medical research and opinion.

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First

M. Toumi, C. François, M. Dabbous, 2019, Journal of market access & health policy.

Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases

C. Lançon, P. Llorca, B. Falissard, 2019, Journal of market access & health policy.

Creating an index to measure health state of depressed patients in automated healthcare databases: the methodology

C. Lançon, P. Llorca, D. Zighed, 2017, Journal of market access & health policy.

Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data

R. Hauser, S. Aballéa, L. Hewitt, 2016, Journal of medical economics.

Memantine enhances autonomy in moderate to severe Alzheimer's disease

B. Rive, M. Vercelletto, C. François, 2004, International journal of geriatric psychiatry.

lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015 .

lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015 .

lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015 .

Oncology from an HTA and Health Economic Perspective.

M. Toumi, C. François, Junwen Zhou, 2018, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Can discrete event simulation be of use in modelling major depression?

C. François, G. Duru, N. Despiégel, 2006, Cost effectiveness and resource allocation : C/E.

Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

MondherToumi, C. François, Ruby Han, 2020 .

Prevalence of hepatitis C infection among general population and high-risk groups in the EU/EEA: A systematic review update

MondherToumi, C. François, Junwen Zhou, 2019 .

The Amortization of Funding Gene Therapies: Making the 'Intangibles' Tangible for Patients

S. Simoens, O. Solà-Morales, L. Garrison, 2021, medRxiv.

A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden

B. Jönsson, C. François, M. Löthgren, 2004 .

Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

S. Parikh, C. François, A. Eramo, 2022, BMC Psychiatry.

Patient attitudes toward and goals for MDD treatment: a survey study

M. Opler, C. François, A. Eramo, 2019, Patient preference and adherence.

The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine

C. Lançon, C. François, N. Danchenko, 2017, Current medical research and opinion.

Indirect comparison of clobazam and other therapies for Lennox–Gastaut syndrome

C. François, C. Sapin, J. A. Cramer, 2013, Acta neurologica Scandinavica.